Table 1.
Baseline demographics and secondary endpoints.
| Tacrolimus (n = 168) | Sirolimus (n = 29) | |
|---|---|---|
| Recipient characteristics (mean ± SD unless otherwise specified) | ||
| Age at transplant (years) | 53 ± 9 | 54 ± 9 |
| Gender (male), n (%) | 118 (70) | 19 (65) |
| Race (Caucasian), n (%) | 128 (76) | 18 (62) |
| BMI (kg/m2) | 29 ± 5 | 29 ± 5 |
| Primary disease of hepatitis C, n (%) | 83 (49) | 9 (31) |
| Model for end-stage liver disease (MELD) | 21 ± 6 | 23 ± 6 |
| Pretransplant renal dysfunction | 35 (21)b | 17 (59)b |
| RRT during primary hospitalization, n (%) | 1 (1) | 4 (14) |
| Primary hospitalization/length of stay (median days) | 7a,b | 15a,b |
| Mean duration of maintenance immunosuppression therapy (days) | 361 ± 2 | 354 ± 6 |
aOutlier detected using Grubb's test.
b P < 0.05 between treatment groups.